-
Annual Report 2021
This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…
Read more -
Results for the Fourth Quarter and Preliminary Results for 2021
All time high sales for a quarter, ending at MNOK 112.7 (MNOK 94.2), an increase of 19.7%. Full year 2021 sales ended at a record of MNOK 427.3 (MNOK 363.1). Currency neutral sales of own…
Read more -
Results for the Third Quarter 2021
Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…
Read more -
Pivotal consensus statement for Medistim’s transit time flow technology (TTFM) published in Circulation
Circulation – the official journal of the American Heart Association – and one of the highest ranked journals in cardiology and cardiovascular medicine, published a consensus paper by 19 of the world’s highest renowned specialists…
Read more -
Results for the Second Quarter and First Half 2021
Total revenues for the quarter ended at MNOK 109.8 (MNOK 82.5) and includes MNOK 5.3 granted by the U.S. Paycheck Protection Program related to COVID-19. Total revenues for the first half ended at MNOK 212.4…
Read more -
Adding the popular Pay Per Procedure business model to the MiraQ platform
Medistim utilizes several business models to effectively reach different segments of the US market. In addition to traditional capital investments and purchase of consumables, hospitals can choose to enter leasing agreements or Pay Per Procedure…
Read more -
Results for the First Quarter 2021
Sales for the quarter ended at MNOK 102.6 (MNOK 103.1), on par with the sales record set in Q1 last year. Currency neutral, sales increased by 1.5%. Second best quarter ever for operating result (EBIT)…
Read more -
Annual Report 2020
Following a good start to the year, Medistim experienced a significant impact on operations in the first months of the pandemic. However, due to a solid revenue base and good pipeline activity throughout the second…
Read more -
Results for the Fourth Quarter and Preliminary Results for 2020
Sales for the quarter ended at MNOK 94.2 (MNOK 95.7), a decrease of 1.6%. Sales for 2020 ended at MNOK 363.1 (MNOK 363.7). Operating result (EBIT) for the quarter ended at MNOK 22.1 (MNOK 19.7)…
Read more -
Medistim partners with LivaNova as their new distributor for India
With its population size of about 1,4 billion, India is a large and emerging market for Medistim’s ultrasound devices. Today, about 100,000 coronary bypass (CABG) procedures are performed in India annually, representing a market size…
Read more
PC: Hold CTRL and press + (plus) to enlarge or - (minus) to shrink.
MAC: Hold CMD and press + (plus) to enlarge or - (minus) to shrink.